Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patients
    • Disease patterns
    • Diagnostics
    • Therapy
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Allergology and clinical immunology
    • General Internal Medicine
    • Anesthesiology
    • Angiology
    • Surgery
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Nutrition
    • Gastroenterology and Hepatology
    • Genetics
    • Geriatrics
    • Gynecology
    • Hematology
    • Infectiology
    • Cardiology
    • Nephrology
    • Neurology
    • Emergency and intensive care medicine
    • Nuclear Medicine
    • Oncology
    • Ophthalmology
    • ORL
    • Orthopedics
    • Pediatrics
    • Pharmacology and toxicology
    • Pharmaceutical medicine
    • Phlebology
    • Physical medicine and rehabilitation
    • Pneumology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Radiology
    • Forensic Medicine
    • Rheumatology
    • Sports Medicine
    • Traumatology and trauma surgery
    • Tropical and travel medicine
    • Urology
    • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
  • Log In
  • Register
  • My account
  • Contact
  • English
    • Deutsch
    • Français
    • Italiano
    • Português
    • Español
  • Publications
  • Contact
  • Deutsch
  • English
  • Français
  • Italiano
  • Português
  • Español
Subscribe
Medizinonline Medizinonline
Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patienten
    • Krankheitsbilder
    • Diagnostik
    • Therapie
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Fachbereiche 1-13
      • Allergology and clinical immunology
      • General Internal Medicine
      • Anesthesiology
      • Angiology
      • Surgery
      • Dermatology and venereology
      • Endocrinology and Diabetology
      • Nutrition
      • Gastroenterology and Hepatology
      • Genetics
      • Geriatrics
      • Gynecology
      • Hematology
    • Fachbereiche 14-26
      • Infectiology
      • Cardiology
      • Nephrology
      • Neurology
      • Emergency and intensive care medicine
      • Nuclear Medicine
      • Oncology
      • Ophthalmology
      • ORL
      • Orthopedics
      • Pediatrics
      • Pharmacology and toxicology
      • Pharmaceutical medicine
    • Fachbereiche 26-38
      • Phlebology
      • Physical medicine and rehabilitation
      • Phytotherapy
      • Pneumology
      • Prevention and health care
      • Psychiatry and psychotherapy
      • Radiology
      • Forensic Medicine
      • Rheumatology
      • Sports Medicine
      • Traumatology and trauma surgery
      • Tropical and travel medicine
      • Urology
      • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
Login

Sie haben noch keinen Account? Registrieren

  • BCL-2 Inhibition

The next chapter in blood cancer therapy is opened

    • Congress Reports
    • Hematology
    • Oncology
    • RX
  • 2 minute read

BCL-2 inhibition represents a milestone in the history of blood cancer treatment. Approved for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL), oral small molecule is now also being investigated for the treatment of acute myeloid leukemia (AML) and other indications.

Selective binding of the inhibitor to the anti-apoptotic BCL-2 protein solubilizes proteins such as BIM and BAX. These interact and restore the signaling cascade of programmed cell death. Release of cytochromes c from mitochondria activates caspases, which ultimately lead to apoptosis of the cancer cell. The dependence of malignant cells on survival-promoting proteins has been shown in various hematologic diseases. Overexpression of BCL-2 is found not only in CLL, but also in AML, acute lymphoblastic leukemia (ALL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and various solid tumors, said Prof. Thorsten Zenz, MD, Zurich. It is also now known that BCL-2 inhibitors can induce apoptosis both alone and in combination with agents that increase BCL-2 dependence. This finding was the basis for further studies to investigate the use of venetoclax (Venclyxto®) in other indications.

Therapy development in CLL

In patients with chronic lymphocytic leukemia who progressed on or after ibrutinib, the BCL-2 inhibitor showed promising results in an interim analysis of a multicenter, open-label, non-randomized phase II study. After a median follow-up of 14 months, 65% of patients showed a response according to iwCLL criteria. 9% had a complete remission or complete remission with incomplete recovery in the bone marrow, 3% a nodular partial remission and 52% a partial remission. Progression-free survival was 75% at 12 months, as reported by Assoc. Prof. PD Dr. Dr. Philipp Staber, Vienna.

The current results of the three-year follow-up of the open-label, multicenter, randomized Phase III MURANO study, which evaluated venetoclax in combination with rituximab in patients with relapsed or refractory CLL compared to bendamustine plus rituximab, are also encouraging. Progression-free survival was 71.4% vs. 15.2%. “A higher rate of undetectable minimal residual disease was also achieved at 62%, which was maintained during subsequent monotherapy with venetoclax,” the expert said. “The therapy algorithm for2nd line CLL treatment should be reconsidered according to these data.”

However, something could also be happening in first-line therapy, looking at the results of the randomized phase 3 clinical trial CLL14. The combination of venetoclax plus obinutuzumab versus obinutuzumab plus chlorambucil was studied in CLL patients with coexisting disease who had not received prior treatment. Progression-free survival was 88.2% vs. 64.1% at 24 months.

Alternatives to classical chemotherapy

In acute myeloid leukemia, the BCL-2 inhibitor in combination with azacitidine causes an inhibition of oxidative phosphorylation in AML stem cells, PD Dr. Christoph Röllig, Dresden, explained the mode of action of the effective new therapeutic approach in elderly patients with AML diagnosed for the first time. A combination of venetoclax with HMA could also replace intensive chemotherapy, as suggested by initial study results.

Source: Symposium “The Next Chapter In BCL-2 Inhibition” on the occasion of SOHC, June 28, 2019, Zurich.

 

InFo ONCOLOGY & HEMATOLOGY 2019; 7(4): 30 (published 9/20/19, ahead of print).

Autoren
  • Leoni Burggraf
Publikation
  • InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
  • AML
  • BCL-2 Inhibition
  • CLL
  • leukemia
Previous Article
  • Rare infections of the lung

The worm is in it

  • Congress Reports
  • Infectiology
  • Pneumology
  • RX
View Post
Next Article
  • Psoriasis capitis

The world of topical therapy

  • Dermatology and venereology
  • Education
  • RX
View Post
You May Also Like
View Post
  • 6 min
  • EHA 2025

Progress in multiple myeloma

    • Congress Reports
    • Hematology
    • Oncology
    • RX
    • Studies
View Post
  • 6 min
  • Interstitial lung diseases

Artificial intelligence improves ILD diagnosis

    • Education
    • General Internal Medicine
    • Pneumology
    • Prevention and health care
    • RX
    • Studies
View Post
  • 7 min
  • Management of patients after alloHCST

ERS/EBMT guideline recommendations on pulmonary cGvHD

    • Education
    • General Internal Medicine
    • Genetics
    • Hematology
    • Pneumology
    • RX
    • Studies
View Post
  • 3 min
  • Pyoderma gangraenosum

New study data confirm the validity of the PARACELSUS score

    • Congress Reports
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Geriatrics
    • Orthopedics
    • Prevention and health care
    • RX
    • Studies
    • Surgery
View Post
  • 8 min
  • Progressive multiple sclerosis

New horizons: from BTK inhibitors to remyelination

    • Education
    • Genetics
    • Neurology
    • RX
    • Studies
View Post
  • 6 min
  • Cutaneous and especially facial metastases

Rare manifestations of esophageal carcinoma

    • Cases
    • Dermatology and venereology
    • Education
    • Gastroenterology and Hepatology
    • Oncology
    • RX
    • Surgery
View Post
  • 7 min
  • Rare pulmonary syndromes

Yellow nail and Swyer-James syndrome

    • CME continuing education
    • Dermatology and venereology
    • General Internal Medicine
    • Infectiology
    • Pneumology
    • RX
View Post
  • 3 min
  • IMCAS Refresher: Aging Sciences/Plastic Surgery

Trends in aesthetic and regenerative medicine

    • Congress Reports
    • Dermatology and venereology
    • RX
    • Surgery
Top Partner Content
  • Herpes zoster

    Zum Thema
Top CME content
  • 1
    Yellow nail and Swyer-James syndrome
  • 2
    Individual therapy management for an optimized outcome – an update
  • 3
    Doing sport without fear or risk
  • 4
    UV protection and skin cancer screening – Update 2025
  • 5
    Rare malignancy from a dermatological perspective

Newsletter

Sign up and stay up to date

Subscribe
Medizinonline
  • Contact
  • General terms and conditions
  • Imprint

Input your search keywords and press Enter.